Crescent Grove Advisors’s Abbott ABT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.84M Buy
18,641
+14,738
+378% +$1.54M 0.16% 102
2026
Q2
$354K Buy
3,903
+50
+1% +$4.56K 0.03% 225
2026
Q1
$396K Sell
3,853
-700
-15% -$79K 0.04% 198
2025
Q4
$570K Buy
4,553
+1
+0% +$127 0.05% 166
2025
Q3
$610K Sell
4,552
-23
-0.5% -$3.02K 0.06% 156
2025
Q2
$622K Sell
4,575
-2,244
-33% -$296K 0.06% 149
2025
Q1
$904K Buy
6,819
+301
+5% +$38.3K 0.09% 110
2024
Q4
$737K Buy
6,518
+1,886
+41% +$218K 0.07% 131
2024
Q3
$528K Sell
4,632
-634
-12% -$69.5K 0.05% 158
2024
Q2
$547K Buy
5,266
+500
+10% +$53K 0.06% 157
2024
Q1
$542K Sell
4,766
-149
-3% -$17.1K 0.06% 173
2023
Q4
$541K Buy
4,915
+10
+0.2% +$999 0.06% 163
2023
Q3
$475K Buy
4,905
+143
+3% +$15K 0.06% 178
2023
Q2
$519K Buy
+4,762
New +$508K 0.06% 168
2022
Q1
– Sell
-1,701
Closed -$239K – 293
2021
Q4
$239K Buy
+1,701
New +$218K 0.02% 264
2021
Q3
– Sell
-1,763
Closed -$204K – 269
2021
Q2
$204K Buy
1,763
+74
+4% +$8.63K 0.02% 247
2021
Q1
$202K Buy
+1,689
New +$200K 0.02% 200

Other funds holding ABT

Crescent Grove Advisors's ABT Position: Q3 2026 in Review

Crescent Grove Advisors increased its Abbott (ABT) stake by 378% in Q3 2026, buying an estimated $1.54M and bringing the position to 18,641 shares worth $1.84M. The position accounts for 0.16% of the portfolio, ranked #102.

Crescent Grove Advisors first reported a position in ABT in Q1 2021 and has held it in 17 quarters since. 3,043 funds tracked by Wall St. Rank hold ABT as of Q3 2026.

  • Crescent Grove Advisors held 18,641 shares of Abbott worth $1.84M as of Q3 2026.
  • Crescent Grove Advisors bought 14,738 Abbott shares in Q3 2026, an estimated $1.54M.
  • Abbott made up 0.16% of Crescent Grove Advisors's portfolio in Q3 2026, its #102 holding.
  • Crescent Grove Advisors first reported a position in Abbott in Q1 2021 and has held it in 17 quarters since.
  • 3,043 funds tracked by Wall St. Rank held Abbott as of Q3 2026.

Based on Crescent Grove Advisors's 13F filing for Q3 2026, filed 21 Oct 2026.